EARNING RECAP

Gilead Sciences Inc

#GILD 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted $1.44 est. $1.71 $5.795B est. $5.49B -3.38% ($67.68 closing price) $69.02 $66.75 raises quarterly dividend by 11%; Q4 sales $5.681B $4.5B in U.S; $813M in EU; $398M in other locations; sees FY19 product sales $21.3B- $21.8B
Q3 adjusted $1.84 est. $1.63 $5.596B est. $5.38B +1.63% ($69.74 closing) $70.28 $66.50 raises Fy18 product sales view to $20.8B - $21.3B from $20B- $21B
Q2 adjusted $1.91 est. $1.56 $5.65B est. $5.21B. -.96% ($78.16 closing) $79.04 $76.10 backs FY18 net product sales view of $20B-$21B. CEO MIlligan to stepdown
Q1 $1.48 VS $1.67 $5.09B vs $5.4B -7.83% ($66.88 closing) $68.76 $66.02 2018 sales outlook $20B-$21B
#GILD 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted EPS $1.78 vs $1.67 $5.9B vs $5.74B +2.96% ($82.76 closing) $84.58 $79.35 raises quarterly divident 10% to 57c per share. See FY 18 HCV product sales of $3.5B-$4B vs $9.1B in Fy18
Q3 adjusted $2.27 vs $2.13 $6.5B vs $6.39B -1.04% ($77.07 closing) $77.20 $72.76 FY17 net product sales view $24.5B-$25.5B
Q2 Adjusted EPS $2.56 vs $2.15 $7.1B vs $6.35B +1.04% ($74.96 closing) $75.99 $74.45
Q1 $2.23 Vs $2.38 $6.50B vs $6.62B -2.01% ($67.21 closing) $65.58 $66.27 .

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.